The effect of polymorphisms on genes encoding the CCR5 chemokine receptor and vitamin D receptor (VDR) in human immunodeficiency virus (HIV) type 1 disease progression was analyzed in a cohort of 185 HIV-seropositive injection drug users. Results confirmed a lack of association in patients with HIV disease between CCR5 wtD32 heterozygosity and a slow progression to AIDS and to a CD4 cell count ! A growing body of evidence suggests that host genetic factors play an important role in human immunodeficiency virus (HIV) type 1 infection and disease progression to AIDS [1] . The mechanisms that underlie the apparent resistance to infection found in some people at risk [2, 3] and the variability observed in the rate of disease progression after infection [4] are likely to be multifactorial and to involve both acquired and inherited factors [5] [6] [7] [8] . Among several candidate genes involved in HIV-1 resistance or delayed disease progression are those that mediate immunologic response to virus infection and those involved in virus entry and propagation.
racial groups [9] . Homozygosity for the D32 deletion makes the CD4 T cells resistant to infection from NSI virus strains [10, 11] , although this protection is not absolute [12] .
A decrease in efficiency of HIV-1 entry and replication in CD4 T cells from CCR5 wtD32 heterozygous patients has been described elsewhere [11] . Several studies found that CCR5 wtD32 heterozygous patients may exhibit delayed HIV-1 disease progression [13] [14] [15] . However, these findings have been questioned because they varied by risk group [16, 17] .
Many other factors, including other chemokine receptor alleles [18] and genes [19, 20] and other genes involved in the modulation of the immune response [21] , may interact to determine the rate of disease progression. In this sense, the vitamin D receptor (VDR) gene polymorphisms recently associated with resistance to certain infectious diseases, such as tuberculosis [22] and leprosy [23] , are worth studying as possible candidates involved in HIV-1 infection and disease progression.
In addition to its role in calcium and skeletal homeostasis, the active metabolite of vitamin D, 1,25-dihydroxyvitamin D 3 (1,25- [OH] 2 D 3 ), plays an important role in immune system modulation [24] . Vitamin D promotes monocyte differentiation, stimulates cell-mediated immunity, and inhibits lymphocyte proliferation and secretion of cytokines, such as interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor, and interferon-g, from T cells and IL-12 from macrophages and B cells [24] [25] [26] [27] . The inhibiting effect of vitamin D on the immune response appears to target Th1 cells by preventing their activation and lymphokine production [24] .
Nearly normal levels of circulating 1,25-(OH) 2 D 3 have been reported in HIV-1-infected patients without AIDS-related events. [29] . Taken together, these data emphasize the importance of 1,25-(OH) 2 D 3 in the modulation of the immune response and its possible relationship with HIV-1 pathogenesis. The immunomodulatory actions of the vitamin D hormone are mediated by interaction with its specific intracellular receptor, which is expressed in rested and activated lymphocytes [30] . Three restriction fragment length polymorphisms (RFLPs), corresponding to the BsmI, ApaI, and TaqI restriction enzymes, and a poly (A) microsatellite polymorphism have been described in the 3 untranslated region (UTR) of the VDR gene. These exhibit almost full linkage disequilibrium in white populations [31, 32] , making them interchangeable 3 UTR markers for this locus. Variability in the 3 UTR of the VDR gene has been described in association with bone mineral density and predisposition for osteoporosis in postmenopausal women [31] , with parathyroid hormone function in patients with different degrees of chronic renal failure [33] , with incidence and aggressiveness of prostate [32] and breast [34] cancers, and with the aforementioned resistance to tuberculosis and leprosy.
This study focused on the prevalence of the D32 deletion polymorphism of the CCR5 gene and that of the BsmI polymorphism, representing the variability of the 3 UTR of the VDR gene, within a cohort of 185 HIV-1-seropositive injection drug users (IDUs). We related the results to susceptibility to HIV-1 infection and rates of disease progression. Interactions between these 2 polymorphic loci were also studied.
Subjects and Methods
Population study. The Lleida AIDS Cohort is a seroprevalent cohort of HIV-infected patients. For each patient, the first HIV-1-positive test was obtained between 1982 and 1998. All seropositive patients seen at the HIV/AIDS Unit of the Hospital Universitari Arnau de Vilanova, Lleida (Catalunya, Spain), since 1986 were invited to participate. Of 461 subjects, 444 (96%) were white (of European origin), and 17 (4%) were of African origin. Most subjects (330 [72%]) were in the IDU risk group, 105 (23%) were in the heterosexual risk group, and other risk groups had minor representation (percentages throughout may total 1100 because of rounding): 14 homosexuals (3%) and 12 recipients of blood and hemoderivatives (3%). There were 324 men and 137 women.
Only HIV-positive white IDUs were included in this study, because genotype prevalence varies by race [9, 32] . Natural history of the illness also varies significantly by risk group. Given the natural history of HIV infection, seropositive patients could have been infected a few months to several years before their cases were recorded. For any given patient, the degree of imprecision in their seroconversion date declined the nearer the date of their first positive test was to the period of maximum incidence of HIV disease in their geographic area. With this in mind, and to minimize the limitation associated with lack of a seroconversion date, we limited our study to patients whose first positive HIV test result was obtained between 1982 and 1991. The majority of patients in the study (140 [76%] of 185) became HIV-1 positive between 1986 and 1991, corresponding to the period of peak incidence of HIV-1 infection in IDUs in Catalonia [35] . A patient's age at the first positive HIV test result should be taken into consideration when evaluating the imprecision of the seroconversion date. The mean age of the cohort patients at the first HIV-1-positive test was 24 years (interquartile range [IQR], 21-27 years; table 1]), and a significant proportion (16%) were !20 years old. From this, we deduced that the patients selected had been infected only a short time before their first HIV-1-positive test result. These selection criteria also extended the minimum follow-up period to 7 years. In total, 185 patients fulfilled all inclusion criteria.
Follow-up for each patient was from the first HIV-positive test result to the last recorded visit or death. Patients were considered to be lost from follow-up when the date of the last recorded visit was 6 months before the end of the study (March 1999) . The median follow-up time was 128 months (minimum, 85 months; maximum, 198 months). At enrollment, patients were asked to return for an interview and for a clinical examination and blood sample every 3 months. Our treatment policy was to administer antiretroviral drugs when patients had a CD4 cell count !500 cells/mL. Of the 185 patients selected for study, 31 (17%) were free of treatment by the end the study, 18 (10%) were being treated with 2 base analogues a mean of 76.8 months after HIV-positive test results, and 136 (74%) were being treated with a combination of 2 base analogues and a protease inhibitor a mean of 84.6 months after HIV-positive test results. Treatment was ongoing a mean of 52 months for those receiving 2 base analogues and 43 months for those treated with a combination of 2 base analogues and a protease inhibitor. We reviewed all clinical records of HIV-1-related events, use of antiretroviral therapy, and routine measurements.
HIV-1 disease progression was analyzed by 2 clinical AIDSdefining outcomes: the CDC 1987 and CDC 1993 AIDS-defining criteria. The CDC 1993 definition is less restrictive, because it includes a CD4 cell count of !200 cells/mL as an AIDS-defining criterion [36, 37] . A first drop in CD4 cell count to !200/mL and start of antiretroviral treatment were also used as separate outcomes.
HIV-1 antibodies were detected in serum by use of a commercial Microparticle EIA (MEIA; Abbott Laboratories) and were confirmed by a Western blotting assay (INNO-LIA HIV confirmation; Innogenetics). Serum virus load was measured by the Amplicor HIV-1 Monitor test (Roche Molecular Systems), following the manufacturer's instructions. Virus load was analyzed on a base 10 logarithmic scale; values below the level of detection (500 copies/ mL) were set as 499 copies/mL. CD4 cell counts were investigated on a fluorescence-activated cell sorter (Becton Dickinson). A control population of 120 healthy white HIV-1-negative persons was recruited for this study from voluntary blood donors.
Genotyping. Genomic DNA, extracted from peripheral blood lymphocytes with the KG-Midi extraction kit (Camgen), was used in polymerase chain reaction (PCR) protocols developed to detect the previously described BsmI RFLP at the VDR locus and the 32-bp deletion polymorphism at the CCR5 locus. PCR primers were based on the published VDR sequence (GenBank accession no. AC004466) and CCR5 sequence (GenBank accession no. U57840) and were designed by Primer3 on-line software [38] . Primer sequences were as follows: hvdr3 (5 -AGC GTC CAG GCG ATT CGT AG-3 ) and hvdr4 (5 -ATA GGC AGA ACC ATC TCT CAG-3 ), which amplified a 192-bp fragment surrounding the BsmI polymorphic site [33] . Primers CCR5L (5 -TTA AAA GCC AGG ACG GTC AC-3 ) and CCR5R (5 -GAC CAG CCC CAA GAT GAC TA-3 ), which amplified 2 fragments of 204 and 172 bp, corresponded, respectively, to wt and deleted CCR5 alleles. Cycling conditions were 96ЊC for 5 min in all reactions, followed by 35 cycles at 94ЊC for 30 s, 65ЊC for 45 s, and 72ЊC for 45 s (BsmI) or 30 cycles at 94ЊC for 30 s, 58ЊC for 30 s, and 72ЊC for 30 s (CCR5 D32). A final extension step of 72Њ for 10 min was applied in all reactions. BsmI alleles were referred to as "B," corresponding to the absence of the BsmI restriction site, or "b," corresponding to the presence of the BsmI restriction site; these were detected by single-strand conformation polymorphism analysis [39] . Amplified fragments for the CCR5 locus were resolved in 2% agarose gel electrophoresis and were visualized by ethidium-bromide staining.
Statistical analysis.
The Hardy-Weinberg equilibrium was tested by comparing expected and observed genotype frequencies by the x 2 test. We compared the distribution of genotypes between patients and control persons by contingency table analysis. Distributions of sex, treated patients, and AIDS-defining illness were compared among genotypes by x 2 test. The lowest CD4 cell count and highest virus load reached during follow-up were recorded for each patient. Differences between genotypes for all values were compared by Mann-Whitney U test.
We explored the relationship between genetic background and HIV-1 disease progression by analyzing the distribution of CCR5 and VDR genotypes among HIV-positive IDUs categorized according to disease status as progressors or nonprogressors. Progressors were defined as HIV-positive IDUs who either developed AIDS, as defined in the CDC 1987 or 1993 criteria; experienced declines in CD4 cell counts to !200 cells/mL during follow-up; or needed antiretroviral treatment. Nonprogressors remained AIDS free, had 1200 CD4 cells/mL, or did not need antiretroviral treatment after a minimum outcome-free follow-up time of 7 years (84 months). We used Fisher's exact test to assess differences in genotype distribution among patients by progression group.
We used basic conservative grouping criteria because of the limitations imposed by the data available. In the group of progressors, we did not distinguished between those progressing rapidly and those who progressed slowly, since we did not know the exact timing of HIV-1 infection. Furthermore, our requirement for longterm infection tended to restrict analysis to HIV survivors, thereby excluding true rapid progressors who likely would have died before study inclusion. In the nonprogressor group, we did not distinguish between subjects with slow progression and those with long-term nonprogression. To define this group, we chose a minimum 7-year outcome-free follow-up time, which corresponds to the mean time for reaching outcome in our patient population. We consider this period adequate to permit definition of a sufficiently homogenous group. When we envisaged a longer outcome-free follow-up time (8-9 years), the results were similar, but the power of the analysis was significantly reduced (data not shown). We believe that, by following these basic criteria, we could detect any potential differences in genotype prevalence in the 2 patient groups.
We also studied HIV-1 disease progression profiles at the aforementioned outcomes for each genotype by Kaplan-Meier survival analysis. Mean values for survival time were calculated [40] , and differences were compared by log-rank test. In the whole cohort of HIV-positive IDUs ( ), survival analysis was computed n p 185 from the time of the first available HIV-1-positive test. In the subgroup of patients undergoing antiretroviral treatment (n p ), survival analysis was computed from the date on which ther-154 apy began.
Cox proportional hazard ratios for genotypes at CCR5 and VDR loci were estimated by using a univariate Cox proportional hazard model (crude analysis) or by adjusting for sex, age at first HIV-1-positive test result [41] , and antiretroviral treatment status (adjusted analysis of the whole cohort for CDC 1987, CDC 1993, and !200 CD4 cells/mL outcomes); adjusting for sex and age at first HIV-1-positive test result (adjusted analysis of the whole cohort for start of antiretroviral treatment); or by adjusting for sex, age at first HIV-1-positive test result, and time before antiretroviral treatment (adjusted analysis of the cohort of patients undergoing ther-apy for CDC 1987, CDC 1993, and !200 CD4 cells/mL outcomes). Interaction between genotypes was included in all analyses.
Patients who did not reach an end point were censored at the time of their last recorded visit (follow-up end) or date of death (not caused by AIDS). Patients lost from follow-up who did not reach an outcome were censored at the time of the last recorded visit (20 patients for CDC 1987, 17 for CDC 1993, 18 for decline in CD4 cell count to !200 cells/mL, and 4 for start of antiretroviral treatment). The observation period ended in March 1999. Statistical analyses were done with SPSS software.
was consid-P р .05 ered to be statistically significant.
Results

Distribution of CCR5 and VDR genotypes in healthy control persons and HIV-positive IDUs.
The prevalence of CCR5 and VDR genotypes was investigated among 120 healthy control persons and 185 HIV-positive IDUs. Among the healthy control persons, 98 (81.6%) had CCR5 wtwt homozygosity, 19 (15.8%) had CCR5 wtD32 heterozygosity, and 3 (2.5%) had CCR5 D32D32 homozygosity. Although the frequency of CCR5 D32D32 homozygosity was higher than that expected for a nonexposed population, the few persons of this genotype could account for this apparent discrepancy. The distribution of genotypes for the CCR5 polymorphism in HIV-positive IDUs was 158 (85.4%) CCR5 wtwt homozygous and 27 (14.6%) CCR5 wtD32 heterozygous patients. Genotypic frequencies in each group were in Hardy-Weinberg equilibrium and were in accord with data for a white population described elsewhere [13] . No CCR5 D32D32 homozygosity was observed among HIV-positive IDUs. Data reported earlier indicated that persons homozygous for the D32 allele are strongly protected against HIV-1 infection [2, 10, 11, 14] .
The distributions of VDR genotypes among healthy control persons (VDR-BB, 13.4%; VDR-Bb, 55.8%; and VDR-bb, 30.8%) and HIV-positive IDUs (VDR-BB, 17.3%; VDR-Bb, 46.5%; and VDR-bb, 36.2%) were in Hardy-Weinberg equilibrium. There were no significant differences in VDR genotype frequencies between control persons and patients, suggesting that polymorphisms of the VDR locus do not affect initial HIV-1 infection. CCR5 and VDR polymorphisms were independently distributed in both healthy control persons and HIVpositive IDUs ( and , respectively). The P p .49 P p .126 prevalence of CCR5 wtD32 heterozygosity among VDR genotypes was 6.6% in VDR-BB, 13.7% in VDR-Bb, and 24.4% in VDR-bb control subjects and 6.3% in VDR-BB, 13% in VDRBb, and 21% in VDR-bb HIV-positive IDUs.
HIV-1 clinical characteristics of the study population in relation to CCR5 and VDR genotypes. Among the 185 patients analyzed, 7 died, and 20 abandoned the cohort during followup. The prevalence of CCR5 wtD32 heterozygosity in nonprogressors was higher than that in progressors but reached statistical significance only for start of antiretroviral treatment ( , Fisher's exact test; figure 1A ). According to our P p .005 treatment policy, the patients who did not receive treatment were those who progressed most favorably.
The distribution of VDR genotypes among nonprogressors and progressors was similar for VDR-Bb heterozygous patients (48% vs. 43% for CDC 1987, 52% vs. 41% for CDC 1993, 52% vs. 39% for CD4 cell count, and 42% vs. 47% for start of antiretroviral treatment) and VDR-bb homozygous patients (36% vs. 37% for CDC 1987, 36% vs. 37% for CDC 1993, 37% vs. 35% for CD4 cell count, and 42% vs. 35% for start of treatment). In contrast, the prevalence of VDR-BB homozygotes among nonprogressors was lower than that in progressors for all outcomes considered (16% vs. 20% for CDC 1987, 13% vs. 22% for CDC 1993, 11% vs. 27% for CD4 cell count, and 16% vs. 17% for start of antiretroviral treatment; figure 1B) . We constructed tables to test for differences in the dis-2 ϫ 2 tribution of VDR-BB and non-VDR-BB genotypes (considering VDR-Bb heterozygotes and VDR-bb homozygotes together) between progressors and nonprogressors. VDR-BB homozygosity was associated with decline of CD4 cell counts to !200 cells/mL, with an odds ratio (OR) of 2.4 (95% confidence interval [CI], 1.3-4.7), compared with non-VDR-BB homozygosity (Fisher's exact test, ; figure 1B ). This result P p .009 seems to suggest a more rapid disease progression for VDR-BB homozygotes.
We also analyzed the distribution of CCR5 genotypes among progressors and nonprogressors by VDR genotype (figure 2). Percentage of CCR5 wtD32 heterozygotes among patients who remained free of antiretroviral treatment was higher than that among patients who started to receive therapy ( , Fisher's exact test). Per-P p .005 centage of VDR-BB homozygotes among patients whose CD4 cell counts fell below 200 cells/mL was higher than that among patients who maintained a cell count 1200 CD4 cells/mL ( , Fisher's P p .009 exact test). Data in parentheses are no. of persons in each genotype/ total subjects in each outcome category. CI, confidence interval; OR, odds ratio.
No differential distribution of CCR5 wtD32 genotype was observed between progressors and nonprogressors in the 32 patients with a VDR-BB genetic background ( figure 2A) . However, the low number of CCR5 wtD32 heterozygotes among VDR-BB subjects may have prevented the detection of a differential distribution of this genotype. In the 86 subjects with a VDR-Bb genetic background, CCR5 wtD32 heterozygotes were overrepresented among those who did not need antiretroviral treatment (OR, 0.31; 95% CI, 0.1-0.9;
; fig-P p .058 ure 2B). Furthermore, when VDR-BB and VDR-Bb subjects were combined, no differential distribution of the CCR5 wtD32 genotype was observed between progressors and nonprogressors (data not shown). Finally, in the 67 patients who had a VDR-bb genetic background, a protective effect of CCR5 wtD32 genotype was observed ( figure 2C ). The prevalence of CCR5 wtD32 heterozygotes in nonprogressors was greater than that in progressors for all outcomes considered. In patients with a VDR-bb genetic background, CCR5 wtD32 genotype was associated with protection against AIDS according to CDC 1993 criteria (OR, 0.28; 95% CI, 0.09-0.91; ), against P p .033 decline in CD4 cell count to !200 cells/mL (OR, 0.26; 95% CI, 0.06-1.1; ), and against starting antiretroviral treat-P p .062 ment (OR, 0.2; 95% CI, 0.05-0.76;
). P p .022
HIV-1 disease progression and CCR5 and VDR genotypes.
Survival analysis was performed to test for association between CCR5 and VDR genotypes with disease progression to outcomes in all HIV-positive IDUs. The mean time to AIDS for CCR5 wtD32 heterozygous patients was 164 months for AIDS CDC 1987 and 142 months for AIDS CDC 1993 categories. CCR5 wtD32 heterozygotes had !200 CD4 cells/mL at a mean of 146 months and started antiretroviral treatment at a mean of 104 months. However, time to progression was faster in CCR5 wtwt homozygotes (157, 130, 144, and 94 months for CDC 1987, CDC 1993, CD4 cell count, and start of antiretroviral treatment, respectively), although these differences were not statistically significant ( , , , and P p .22 P p .16 P p .28 , log-rank test, for CDC 1987, CDC 1993, CD4 cell P p .17 count, and start of treatment, respectively). Cox proportional hazard ratios for progression to these outcomes were not statistically significant.
VDR-BB homozygotes progressed faster than non-VDR-BB homozygotes to all outcomes considered. The mean time to AIDS for VDR-BB homozygotes was 140 months for CDC 1987 and 111 months for CDC 1993. Patients reached !200 CD4 cells/mL after a mean of 117 months and started antiretroviral treatment after a mean of 83 months. Even so, the time to progression was slower in those with non-VDR-BB homozygosity. VDR-Bb heterozygotes progressed to outcome after 164, 141, 155, and 101 months for CDC 1987, CDC 1993, CD4 cell count, and start of antiretroviral treatment, respectively. VDR-bb homozygotes progressed to outcome after 149, 126, 138, and 94 months for CDC 1987, CDC 1993, CD4 cell count, and start of antiretroviral treatment, respectively. Differences in mean time to AIDS CDC 1993 and to CD4 cell count declines were statistically significant only when VDR-BB homozygotes were compared with non-VDR-BB homozygotes (VDR-Bb and VDR-bb considered together; and P p .043 , respectively, log-rank test). By univariate and ad-P p .005 justed hazard ratios, VDR-BB homozygosity was associated with progression to AIDS (CDC 1993) and decline in CD4 cell count to !200 cells/mL ( figure 3A and 3B) . These results support the reported associations between VDR-BB genotype and decline in CD4 cell count to !200 cells/mL and the more rapid disease progression attributable to VDR-BB homozygotes. Cox analysis for interaction between genotypes was of borderline significance for the outcome of !200 CD4 cells/mL ( ). P p .061 Survival analysis was used to compare disease progression among CCR5 genotypes in patients grouped by VDR genotype. P p .56 cell count, and start of antiretroviral treatment, respectively, log-rank test). Statistically significant differences were found only in the subpopulation of 67 patients with VDR-bb genotype. The mean time to AIDS CDC 1993 and to declines in CD4 cell counts to !200 cells/mL for CCR5 wtD32 heterozygous patients was longer than that in CCR5 wtwt homozygotes ( and , respectively, log-rank test; figure 3C P p .029 P p .041 and 3D). The smaller number of patients analyzed in the VDR-BB group may not have allowed detection of statistically significant differences. This was not so in the VDR-Bb group, in which the number of patients was similar to that analyzed in the VDR-bb group, in which we detected significant differences. Kaplan-Meier and Cox analyses also were performed for non-VDR-bb subjects (VDR-BB and VDR-Bb combined), but no significant differences were observed (data not shown). These results support the idea of protection against disease progression for the CCR5 wtD32 genotype in VDR-bb subjects previously observed in the population-based study.
HIV-1 disease progression in patients receiving antiretroviral treatment. Because a significant proportion of patients were receiving antiretroviral treatment throughout the study (n p ), we analyzed HIV-1 disease progression to AIDS by CDC 154 1987 and CDC 1993 criteria or to declines in CD4 cell counts in this subpopulation. The distribution of genotypes for the CCR5 polymorphism among HIV-positive IDUs undergoing antiretroviral treatment was 137 (89%) of CCR5 wtwt homozygotes and 17 (11%) of CCR5 wtD32 heterozygotes. The prevalence of VDR genotypes in this subpopulation was 27 VDR-BB (17.5%), 73 VDR-Bb (47.4%), and 54 VDR-bb (35.1%). These figures do not differ significantly from those obtained for the total cohort. CCR5 wtD32 heterozygous patients were no differently distributed among progressors and nonprogressors for the outcomes considered; however, VDR-BB homozygotes were overrepresented in progressors when we considered AIDS CDC 1993 (20 [23%] of 87 progressors vs. 7 (10%) of 67 nonprogressors) and CD4 cell count (20 [27%] of 73 progressors vs. 7 [9%] of 81 nonprogressors) as outcomes. In accordance with the total cohort-based results, VDR-BB homozygosity also was associated with progression to AIDS CDC 1993 (OR, 2.2; 95% CI, 0.98-5;
) and with !200 CD4 cells/mL (OR, 3.2; P p .054 95% CI, 1.4-7; ) in patients receiving antiretroviral P p .003 treatment. However, the distribution of CCR5 genotypes among progressors and nonprogressors was not statistically different from that of patients grouped by VDR genotype.
Survival analysis and Cox proportional hazard ratios were determined for patients receiving antiretroviral treatment from start of treatment to AIDS by CDC 1987 or CDC 1993 or to declines in CD4 cell counts. Mean time to outcome and hazard ratio were not significantly different among CCR5 genotypes. VDR-BB homozygotes progressed more rapidly than non-VDR-BB homozygotes when AIDS CDC 1993 and CD4 cell counts were considered as outcomes ( and , P p .022 P p .002 respectively, log-rank test; figure 4). Univariate and adjusted hazard ratios for VDR-BB homozygotes progressing to CD4 cell counts of !200 cells/mL were statistically significant. No statistically significant differences for mean time to outcome among CCR5 genotypes were observed in the 54 treated patients with VDR-bb genotype.
The less favorable disease progression attributable to VDR-BB homozygotes also applied to the subpopulation of patients receiving treatment. The few treated patients with VDR-bb genotype can be accounted for by the fact that no association was detected between CCR5 wtD32 genotype and slower disease progression.
Discussion
Our goal was to investigate both the independent and combined effects of the 32 bp deletion polymorphism of the CCR5 gene and the BsmI RFLP of the VDR gene on HIV-1 infection and disease progression in a cohort of 185 HIV-positive IDUs. We did not find any HIV-positive IDU homozygotes for the D32 allele. This confirms that homozygous CCR5 D32D32 persons have strong protection against HIV-1 infection. CCR5 wtD32 heterozygosity showed a similar prevalence in healthy control persons and HIV-positive IDUs, indicating that heterozygotes are not protected against HIV-1 transmission. Results of other studies have shown that CCR5 D32 carriers are not protected against either homosexual [13] or heterosexual [16] HIV-1 transmission. Genotype distribution of the VDR polymorphism was not significantly different between healthy control persons and HIV-positive IDUs. This suggests that BsmI polymorphism is not involved in initial HIV-1 infection. As expected on the basis of their chromosome locations, polymorphisms at the CCR5 (3p21) and VDR (12q12-q14) loci were independently distributed in both healthy control persons and HIV-positive IDUs. Combined genotype frequencies at these 2 loci were not significantly different when healthy control per- sons were compared with HIV-positive IDUs, indicating there was no effect on susceptibility to HIV-1 infection attributable to any combination of these 2 polymorphisms.
Start of antiretroviral treatment was considered as an outcome, to test for association between disease progression and genotypes in drug-naive patients. We detected only an overrepresentation of CCR5 wtD32 heterozygous patients in those who did not need treatment. This seems to suggest a better prognosis for this genotype. Even so, this conclusion was not supported by the survival and Cox analyses, in which time to start of antiretroviral treatment was not significantly different among CCR5 genotypes.
Unlike the protective effect of the CCR5 wtD32 genotype observed in several homosexual and heterosexual cohort studies, in ours, as in others in which IDUs were analyzed, HIV-1 disease progression to AIDS or to CD4 cell count decline was not definitely associated with CCR5 genotype [17] . Several hypotheses have been proposed to explain the lack of protection from the CCR5 wtD32 genotype found in IDUs. These include a lesser dependence on CCR5 coreceptor use for IDUs, differences in the immunologic status of patients in different groups, and differences in transmission routes [17] .
There is growing evidence that CCR5 expression level modulates HIV-1 infectability and influences the clinical course of infection. As reported by de Roda Husman et al. [42] , CCR5 expression increases during HIV-1 infection, allowing higher levels of HIV-1 replication, which may, in turn, accelerate disease progression. In vitro analyses support the belief, based on greater production of CCR5 chemokine receptor in CCR5 wtwt homozygotes than in CCR5 wtD32 heterozygotes, that CCR5 genotype influences HIV-1 disease progression [42] [43] [44] . Even so, an extended overlap exists in CCR5 expression levels among CCR5 genotypes, which indicates that additional factors are involved in the modulation of CCR5 coreceptor expression. As proposed by Paxton and Kang [45] , CCR5 expression phenotype rather than the CCR5 genotype is often the determinant in the progression to HIV-1 disease. The CCR5 expression phenotype is affected by the immune status of the subject as a consequence of the expression pattern of chemokines or chemokine receptor genes and other genes involved in the modulation of the immune response. Following this rationale, we analyzed the role of the BsmI polymorphism of the VDR gene in HIV-1 disease progression and its interaction, if any, with the CCR5 coreceptor genotype.
A less favorable disease progression could be attributed to VDR-BB homozygotes, as reflected by the higher prevalence of this genotype in patients reaching outcome and their faster progression to AIDS and to declines in CD4 cell counts. These findings provide strong evidence that genetic variation at the VDR locus may affect the rate of progression to HIV-1 infection. Homozygosity for the BsmI B allele of the VDR locus could be considered a risk factor for less favorable progression in HIV-1 disease.
There is no definite evidence of how BsmI VDR alleles differentially mediate vitamin D response. Allelic variation in the 3 UTR of the VDR gene may affect message stability and translation efficiency and could subsequently lead to variations in cell responsiveness to vitamin D. Alternatively, genetic variation in the 3 UTR could be a marker for a hitherto unknown locus that is in linkage disequilibrium with the 3 UTR polymorphisms. Conflicting results have shown that mRNA levels are higher [31, 46] , lower [47] , or no different [48, 49] in VDR-BB homozygotes versus VDR-bb homozygotes.
The high HIV-1 disease progression rates found in VDR-BB homozygotes could be interpreted as showing that persons who carry the VDR-BB genotype have a reduced response to the immunosuppressive actions of vitamin D and allow the activation of Th1 cells. Since Th1 cells express CCR5 coreceptor [44] , they could be more efficiently infected by HIV-1 and promote disease progression. Under Th1 activation, CCR5 expression levels in CCR5 wtD32 heterozygotes could overlap with levels expressed in CCR5 wtwt homozygotes. Therefore, overlapping CCR5 phenotypes would not allow the manifestation of the protective effect of low-expression variants of the CCR5 gene. With this rationale, mirror behavior could be expected if the immunosuppressive effects of vitamin D could correctly prevent the Th1 activation of CD4-expressing CCR5 coreceptor cells. Under these conditions, differential expression of CCR5 coreceptor attributed to CCR5 genotypes would be manifested as a lower CCR5 coreceptor density in CD4 cells of CCR5 D32 carriers, as opposed to CCR5 wtwt homozygotes. This would be manifested as a delayed disease progression in CCR5 D32 carriers.
By following this hypothesis, we could expect the detection of CCR5 genotype effect on HIV-1 disease progression to be influenced by VDR genotype, as shown when disease progression was analyzed in relation to CCR5 genotype in patients grouped by VDR genotype. No differences in disease progression were observed for CCR5 genotypes in patients with either VDR-BB or VDR-Bb genotypes. However, in patients carrying the VDR-bb genotype, disease progression to AIDS (CDC 1993) and declines in CD4 cell counts to !200 cells/mL were delayed in CCR5 wtD32 heterozygous patients, when compared with CCR5 wtwt homozygotes. These results were reinforced by the greater prevalence of CCR5 wtD32 heterozygous patients observed in nonprogressors than in progressors with VDR-bb genetic background.
In addition to the hypothesis involving the immunosuppressor activity of vitamin D, the pleiotropic effects of this vitamin compel us to consider other hypotheses. A recent report that men receiving highly active antiretroviral therapy including a protease inhibitor had a higher incidence of osteopenia and osteoporosis [50] suggests a possible link between vitamin D and anti-AIDS drug actions. As we have shown, VDR-BB homozygosity is associated with a greater risk of disease progression in patients receiving antiretroviral treatment. As a consequence, it is possible to envisage modulating drug effects according to a patient's VDR genotype.
After findings of involvement of VDR polymorphisms in infectious diseases such as tuberculosis and leprosy [22, 23] , this report, to the best of our knowledge, is the first that links VDR variants to HIV-1 disease progression. The limitations of this and similar studies must be taken into account when attempting to draw conclusions. Further studies will be required with additional IDU cohorts and other at-risk groups to clarify the role of VDR polymorphism in HIV-1 pathogenesis and its cooperative interaction with chemokine receptor polymorphisms previously associated with HIV-1 disease progression. Confirmation of the findings that carrying certain VDR genotypes implies more rapid disease progression in HIV-1 infection and that other genotypes allow CCR5 wtD32 heterozygous patients to manifest a delayed disease progression offers new opportunities for designing therapeutic strategies to alter or interrupt progression to AIDS.
